Mirae Asset Global Etfs Holdings Ltd. Arcus Biosciences, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 42,842 shares of RCUS stock, worth $571,940. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,842
Previous 37,572
14.03%
Holding current value
$571,940
Previous $294,000
18.37%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RCUS
# of Institutions
208Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$130 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$87.5 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$79.7 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$53.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$49.2 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $963M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...